Juan Pulido, MD
Pulmonary Disease · Jacksonville Beach, FLNPI 1336293620
Payments from drug & device makers
Across 341 payments — averaging $1724.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$368K
- Actelion Pharmaceuticals US, Inc.$111K
- Medtronic$55K
- AstraZeneca$29K
- Fisher & Paykel Healthcare Inc$15K
- Actelion Pharmaceuticals, Ltd$6K
- plus $5K from 23 others
What the payments were for
- Speaking & faculty fees$92,47771%
- Travel & lodging$27,62321%
- Food & beverage$9,9178%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $367,947 |
| Actelion Pharmaceuticals US, Inc. | 176 | $110,822 |
| Medtronic(2 entities) | 16 | $55,433 |
| AstraZeneca | 49 | $28,509 |
| Fisher & Paykel Healthcare Inc | 18 | $14,682 |
| Actelion Pharmaceuticals, Ltd | 1 | $6,000 |
| Partner Therapeutics, Inc. | 2 | $2,090 |
| Edwards Lifesciences | 3 | $419 |
| Boehringer Ingelheim | 15 | $300 |
| Amgen | 6 | $243 |
| GSK | 13 | $216 |
| Insmed, Inc. | 5 | $205 |
| Inari Medical, Inc. | 1 | $185 |
| Baxter Healthcare | 8 | $165 |
| Nxstage Medical, Inc. | 1 | $142 |
| W. L. Gore & Associates, Inc. | 1 | $141 |
| Abbott | 1 | $130 |
| Verona Pharma, Inc. | 1 | $125 |
| Avanos Medical | 1 | $74 |
| Sanofi | 2 | $46 |
| Philips North America LLC | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $32 |
| Boston Scientific | 1 | $31 |
| ERBE USA Inc | 1 | $30 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$96,634
- OPSUMIT$92,169
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$12,154
- PT100US/myAIRVO 2$2,275
- PT101US/AIRVO2$2,275
- OPT944/Optiflow Nasal Cannula Medium 20Pack$2,275
- OPT970/Optiflow Tracheostomy interface 20pack$2,275
- 900PT561/Air Spiral Breathing Tube Chamber kit$2,275
- WINREVAIR$361
- FASENRA$238
- FLOWTRIEVER CATHETER, S$185
- CT THROMBECTOMY SYSTEM KIT$185
- SAPIEN 3 Ultra RESILIA$165
- NXSTAGE SYSTEM ONE$142
- GORE PROPATEN Vascular Graft$141
- HemoSphere$131
- FREESTYLE LIBRE 3$130
- Ohtuvayre$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$123
- TEZSPIRE$122
How this compares
$588,097 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 25 | $317,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $151,580 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,043 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,909 |
| Tadalafil | 17 | $6,777 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,129 |
| Montelukast Sodium | 26 | $426 |
| Famotidine | 12 | $234 |
| Pantoprazole Sodium | 13 | $112 |
| Methylprednisolone | 11 | $63 |
| Prednisone | 16 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $110,822 | $317,04925 claims |
| GSKTrelegy Ellipta | $216 | $151,580133 claims |
| AstraZenecaBreztri Aerosphere | $28,509 | $14,04317 claims |
| Boehringer IngelheimSpiriva Respimat | $300 | $10,90917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville Beach
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.